Formalin fixation on HER-2 and PD-L1 expression in gastric cancer:A pilot analysis using the same surgical specimens with different fixation times

被引:1
|
作者
Keita Kai
Yukie Yoda
Atsushi Kawaguchi
Akimichi Minesaki
Hironori Iwasaki
Shinichi Aishima
Hirokazu Noshiro
机构
[1] Department of Pathology, Saga University Hospital
[2] Department of Surgery, Saga University Faculty of Medicine
[3] Center for Comprehensive Community Medicine, Saga University Faculty of Medicine
[4] Department of Pathology and Microbiology, Saga University Faculty of Medicine
[5] Department of Otolaryngology - Head and Neck Surgery, Saga University Faculty of Medicine
关键词
Gastric cancer; Programmed death-ligand 1; Human epidermal growth factor receptor 2; Neutral buffered formalin; Fixation time;
D O I
暂无
中图分类号
R735.2 [胃肿瘤];
学科分类号
100214 ;
摘要
BACKGROUND The needs for human epidermal growth factor receptor 2(HER-2) and/or programmed death-ligand 1(PD-L1) evaluations in gastric cancer are dramatically increasing. Although the importance of standardization of sample fixation has been widely recognized, most of the evidence regarding the fixation duration or type of fixing solution are based on breast cancer.AIM To investigate the real effects of fixation conditions on HER-2 testing or PD-L1 testing for gastric cancer using gastrectomy specimens.METHODS Thirty-two patients who underwent gastrectomy for gastric cancer were enrolled.Their resected specimens were each divided into four pieces and fixed in four strictly controlled different durations(6 h, 24 h, and 48 h, and 1 wk) by 10%formalin(n = 22) or 10% neutral buffered formalin(NBF)(n = 10).Immunohistochemistry(IHC) of HER-2 and PD-1 was performed, and a pathology examination was conducted. In the HER-2-immunoreactive cases, all four specimens were subjected to dual-color in situ hybridization(DISH). Five cases were assessed as HER-2-positive by IHC and DISH. We used the cut-off values of 1%, 10%, and 50% to assess the IHC findings of PD-L1.RESULTS No significant difference was observed in comparisons between the shorter fixation period groups(6 h, 24 h, and 48 h) and the prolonged fixation period(1 wk) group in the HER-2 and PD-L1 analyses. Although no significant difference was observed between 10% formalin and 10% NBF within 1 wk of fixation, the superiority of 10% NBF was confirmed in a long-term(> 3 mo) fixation in both the HER-2 and PD-L1 analyses.CONCLUSION In this small-numbered pilot study, prolonged fixation within 1 wk showed no inferiority in HER-2 or PD-L1 testing. However, a large-numbered prospective study is needed to obtain conclusive results.
引用
收藏
页码:419 / 430
页数:12
相关论文
共 50 条
  • [31] The detection value of PD-L1 expression in biopsy specimens and surgical resection specimens in non-small cell lung cancer: a meta-analysis
    Wang, Yang
    Wu, Junqi
    Deng, Jiajun
    She, Yunlang
    Chen, Chang
    JOURNAL OF THORACIC DISEASE, 2021, 13 (07) : 4301 - 4310
  • [32] Clinicopathological Characteristics and Prognostic Value of HER2, PD-L1 and MSI Expression in Curative Resectable Gastric Cancer Patients
    Pereira, M. A.
    Ramos, M. F.
    Faraj, S. F.
    Dias, A. R.
    Cirqueira, C. D.
    Charruf, A. Z.
    Perrotta, F. S.
    Mello, E. S.
    Zilberstein, B.
    Cecconello, I.
    Yagi, O. K.
    Alves, V. A.
    Junior, U. R.
    ANNALS OF SURGICAL ONCOLOGY, 2019, 26 : S190 - S190
  • [33] Claudin-18 status and its correlation with HER2 and PD-L1 expression in gastric cancer with peritoneal dissemination
    Ogawa, Haruki
    Abe, Hiroyuki
    Yagi, Koichi
    Seto, Yasuyuki
    Ushiku, Tetsuo
    GASTRIC CANCER, 2024, 27 (04) : 802 - 810
  • [34] Expression of PD-L1 Is Associated with Inflammatory Microenvironment in Surgical Specimens of Non-Small Cell Lung Cancer
    Simundza, Ivan
    Krnic, Dragan
    Juricic, Josko
    Benzon, Benjamin
    Simundza, Rina
    Stanicic, Ivan Mario
    Capkun, Vesna
    Vukojevic, Katarina
    Durdov, Merica Glavina
    JOURNAL OF PERSONALIZED MEDICINE, 2021, 11 (08):
  • [35] HER2 and programmed deatb-1 ligand-1 (PD-L1) expression in gastric carcinoma
    Oki, Eiji
    Okano, Shinji
    Ando, Koji
    Hiyoshi, Yukiharu
    Ito, Shuhei
    Morita, Maseru
    Maehara, Yoshihiko
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [36] PD-L1 Expression in EBUS-Guided Cytology Specimens of Non-Small Cell Lung Cancer is Not Affected by Type of Fixation: A Study of Matched Pairs
    Gosney, J.
    Haragan, A.
    Chadwick, C.
    Giles, T.
    Grundy, S.
    Tippett, V.
    Gumparthy, K.
    Wight, A.
    Tan, H.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S400 - S400
  • [37] PD-L1 and HER2 Expression in Gastroesophageal Cancer: a Matched Case Control Study
    Beer, Andrea
    Taghizadeh, Hossein
    Schiefer, Ana-Iris
    Puhr, Hannah C.
    Karner, Alexander K.
    Jomrich, Gerd
    Schoppmann, Sebastian F.
    Kain, Renate
    Preusser, Matthias
    Ilhan-Mutlu, Ayseguel
    PATHOLOGY & ONCOLOGY RESEARCH, 2020, 26 (04) : 2225 - 2235
  • [38] Evaluation of programmed death-ligand 1 (PD-L1) expression in gastric and gastrooesophageal junction cancer using paired resection and biopsy specimens
    Rhee, Y. -Y.
    Kim, H. S.
    Kim, S. H.
    VIRCHOWS ARCHIV, 2018, 473 : S176 - S176
  • [39] Nationwide survey on HER2 and PD-L1 testing practices in gastric cancer across Japan
    Abe, Hiroyuki
    Kuwata, Takeshi
    Kushima, Ryoji
    Ushiku, Tetsuo
    GASTRIC CANCER, 2025, 28 (02) : 294 - 300
  • [40] Clinic-Pathological Characteristics and Prognostic Value of PD-L1 and HER2 in Gastric Cancer
    Chen, Ling
    Wang, Liyu
    Li, Xin
    Zhang, Guangtao
    Li, Zhaoyan
    Wang, Yanwen
    DNA AND CELL BIOLOGY, 2021, 40 (02) : 405 - 413